Atopic dermatitis

Atopic Dermatitis (AD) usually starts in early childhood - it is estimated that 10-20% of children and 1-3% of adults are affected, making it one of the most common of all skin conditions. Atopic Dermatitis can have a severe impact on everyday life for both patients and their families. Persistent itching can lead to sleep disturbances, stress, and anxiety, thereby limiting life quality. AD can also have a psychological depraving effect resulting in social unease and reduced work abilities.

AD is a chronic inflammatory skin disease that manifests as a malfunction of the skin layer, reflecting an underlying dysregulated T cell response to allergens. Studies indicate that it is primarily a genetically determined skin condition that can be triggered or enhanced by a wide range of environmental factors. Common symptoms include rash, skin dryness, cracks, crusting, oozing and intense itching. Breaking of the skin-barrier can introduce various microorganisms causing infections, such as infection with Staphylococcus aureus. Staphylococcus aureus has by several studies been linked to intensifying the inflammatory response, thereby amplifying AD symptoms. A significant unmet medical need in AD persists due to the tradeoff between safety, efficacy and convenience of currently available treatments.


ATx20101 OINTMENT uses protonophore properties of niclosamide (ATx201) to treat both the inflammatory and bacterial dimensions of AD. Protonophore activity inhibits cells' energy production, resulting in anti-inflammatory activity in human cells through suppressing differentiated T-cells and inhibiting bacterial growth. ATx201 OINTMENT aspires to become a new treatment paradigm for atopic dermatitis.

UNION Is currently conducting a randomized, double-blinded, vehicle-controlled, parallel group Phase 2b study designed to evaluate the safety and efficacy of ATx201 OINTMENT.


UNI50002 cream, a non-steroidal topical PDE4 inhibitor, is being developed by UNION for atopic dermatitis and are currently in Phase 2.


Clinical findings from a mechanistic study conducted by UNION therapeutics have been published in The Journal of Investigative Dermatology.

For full article, please see: ATx201 modulates biomarkers of skin barrier function and cutaneous inflammation in patients with moderate atopic dermatitis.

Ongoing clinical trials

For ongoing clinical trials, please see: Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD.

Back to Pipeline